India · Delayed Price · Currency is INR Orchid Pharma Earnings Call Transcripts
Fiscal Year 2026
-
FY 2026 saw stable Q4 revenue and EBITDA, but full-year results declined due to industry-wide pricing pressures. Strategic initiatives, including the Dhanuka merger and new product launches, position the company for recovery and growth, with 10–15% sales growth targeted for FY 2027.
-
Q3 FY26 saw a 5% YoY sales decline and margin compression due to global antibiotic market stress and lower regulated market sales. Cost optimization and R&D investments continue, while new launches and the 7-ACA project are expected to drive future growth.
-
Q2 FY26 saw a 13% year-over-year sales decline but sequential improvement, with gross margin compression and EBITDA halved due to weak pricing and inventory revaluation. Strategic acquisition of enmetazobactam rights positions the company for future growth, while the antibiotics market remains under pressure.
-
Q1 FY26 saw a 29% sales decline due to a global antibiotics slowdown, but gross margins were preserved at 42%. The company acquired global rights to Enmetazobactam, expects no debt for the deal, and is focused on disciplined execution and margin protection amid ongoing market contraction.
Fiscal Year 2025
-
Q4 and FY24 saw double-digit sales and EBITDA growth, despite one-time expenses and ongoing pricing pressure. The AMS division remains a drag but is expected to break even in two years, while the 7-ACA project faces a six-month delay. Merger with Dhanuka Labs positions the entity for over INR 1,500 crore revenue.
-
Q3 FY25 saw 15% YoY revenue growth and 26% PAT growth over nine months, with strong volume gains offset by price corrections in key products. Strategic investments in AMS and 7-ACA projects continue, while regulatory milestones and royalty income ramp up.
-
Q2 FY25 sales reached INR 222.7 crores, with H1 sales up 22% year-over-year and EBITDA rising to INR 78.6 crores. Orblicef launched in India, Enmetazobactam sales began in the EU, and capacity expansion projects are on track. Management remains optimistic about future growth.
-
Q1 FY25 saw 34% revenue and 71% EBITDA growth, driven by strong capacity utilization and cost control. New product launches, major CapEx projects, and a Cipla partnership position the company for sustained growth, with full-year revenue expected to rise 20–25%.